申请人:Convergence Pharmaceuticals Limited
公开号:US08288388B2
公开(公告)日:2012-10-16
The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
本发明涉及新型哌嗪衍生物;其制备方法;含有该衍生物的药物组合物;以及利用该衍生物治疗通过阻断Cav2.2钙通道有益的疾病的方法。